Business
Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of INFRONT-2 Phase 2 Open-label Clinical Study
Progranulin Levels Increase to Normal Ranges Multiple Biomarkers of Disease Showed Improvement from Baseline with AL001 Treatment, Including GFAP, a
About this update from Alector, Inc.
[{"type":"text","content":"Progranulin Levels Increase to Normal Ranges Multiple Biomarkers of Disease Showed Improvement from Baseline with AL001 Treatment, Including GFAP, a Prognostic Marker for FTD Associated with Brain Atrophy FTD-GRN Patients Showed a Slowing of Clinical Progression with AL001 Treatment Relative to GENFI2 Matched Control Cohort Data from Phase 2 Study Presented at Clinical Trials of Alzheimer Disease Conference; Management to Host Webcast to Review Results Today at 4:00 p.m. ET BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented encouraging results from the company’s INFRONT-2 Phase 2 clinical trial of AL001 at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference taking place virtually and in Boston. AL001 is a potential first-in-class monoclonal antibody designed to elevate progranulin, a key regulator of immune activity in the brain. Decreased progranulin levels due to genetic mutations are a known cause of frontotemporal dementia (FTD), a rare and rapidly progressing neurodegenerative disease that is the most common form of dementia for people under the age of 60. AL001 is initially being developed for the treatment of adults at risk for or with symptomatic FTD due to a progranulin gene mutation (FTD-GRN). The INFRONT-2 Phase 2 clinical trial was designed to assess the safety and tolerability of chronic dosing of AL001 in symptomatic FTD-GRN patients treated for up to 96 weeks. Highlights from the presentation included observations that: AL001 restored progranulin to normal levels (based on age-matched controls) in both plasma and cerebrospinal fluid (CSF) for the duration of treatment.Multiple biomarkers of lysosomal dysfunction and complement activation, known to be elevated in FTD-GRN, decreased toward normal levels (based on age-matched controls) following treatment with AL001.Glial fibrillary acidic protein (GFAP), a biomarker of astrogliosis that is an indicator of disease and/or injury to the central nervous system, was elevated at baseline and decreased towards normal levels (vs. asymptomatic FTD-GRN mutation carriers following AL001 treatment.AL001 treatment was estimated to slow disease progression at twelve months by 48% based on 12 patients as compared to a matched control cohort of participants from the Gene...